OS Therapies Incorporated (AMEX:OSTX) Financings
Financings
| Raise | Date |
|---|---|
| Debt financing Tranche closed: US$5M raised | Aug 17, 2026 |
| Warrant exercise of common stock purchase warrants exercised or pre-funded for cash under warrant inducement Announced: US$7.53M · Ceros Capital Markets, a division of Ceros Financial Services, Inc. Dealers: Ceros Capital Markets, a division of Ceros Financial Services, Inc. (lead) Use of proceeds: OST-HER2 regulatory filings and commercial preparation, OS Animal Health spinoff preparations, and general corporate purposes | Jan 12, 2026 |
| Warrant exercise of outstanding warrants with $1.12 exercise price exercised under warrant inducement and exchange offer Closed: US$3.7M raised · US$1.12 a share · Warrants at US$3 · Ceros Financial Services, Inc. Dealers: Ceros Financial Services, Inc. (lead) Use of proceeds: Primarily to accelerate OST-HER2 commercial launch preparations in osteosarcoma in the United States | Sep 2, 2025 |
| Shares under Equity Purchase Agreement (equity line of credit) Cancelled: raise Buyers: Square Gate Capital Master Fund, LLC — Series 3 | Aug 26, 2025 |
| At-the-market programme of common stock Announced: up to US$18M · B. Riley Securities +1 Dealers: B. Riley Securities, JonesTrading | Aug 19, 2025 |
| Warrant exercise of warrants exercised under warrant exercise inducement and exchange offer Closed: US$1.76M raised · US$1.12 a share · Warrants at US$3 for 60 months Use of proceeds: Regulatory and pre-commercial work for OST-HER2 approvals, OS Animal Health alternatives, OST-504 study close-out, AI tADC modeling, general corporate | Jul 14, 2025 |